Sandoz Group AG (SDZNY)
| Previous Close | 45.46 |
| Open | 45.46 |
| Bid | 45.93 x 40000 |
| Ask | 46.21 x 40000 |
| Day's Range | 45.46 - 46.15 |
| 52 Week Range | 27.79 - 46.80 |
| Volume | |
| Avg. Volume | 50,410 |
| Market Cap | 19.752B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | Oct 30, 2024 |
| Forward Dividend & Yield | 0.50 (1.09%) |
| Ex-Dividend Date | May 03, 2024 |
| 1y Target Est | N/A |
GlobeNewswireSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has g
- GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (
- GlobeNewswire
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Admi
